Nature Communications (Aug 2020)
The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells
- Xiao Gao,
- Qingwei Wang,
- Ying Wang,
- Jiang Liu,
- Shuang Liu,
- Jian Liu,
- Xingli Zhou,
- Li Zhou,
- Hui Chen,
- Linian Pan,
- Jiwei Chen,
- Da Wang,
- Qing Zhang,
- Shihui Shen,
- Yu Xiao,
- Zhipeng Wu,
- Yiyun Cheng,
- Geng Chen,
- Syeda Kubra,
- Jun Qin,
- Lan Huang,
- Pei Zhang,
- Chuangui Wang,
- Robb E. Moses,
- David M. Lonard,
- Bert W. O’ Malley,
- Fuad Fares,
- Bianhong Zhang,
- Xiaotao Li,
- Lei Li,
- Jianru Xiao
Affiliations
- Xiao Gao
- East China Normal University and Shanghai Changzheng Hospital Joint Research Center for Orthopedic Oncology, East China Normal University
- Qingwei Wang
- Department of Surgery, Department of Physiology & Cell Biology, College of Medicine, Davis Heart and Lung Research Institute, Wexner Medical Center, The Ohio State University
- Ying Wang
- The Institute of Aging Research, School of Medicine, Hangzhou Normal University
- Jiang Liu
- The Institute of Aging Research, School of Medicine, Hangzhou Normal University
- Shuang Liu
- Department of Hematology, Guangdong Second Provincial General Hospital
- Jian Liu
- Reproductive & Developmental Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS)
- Xingli Zhou
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Li Zhou
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Hui Chen
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Linian Pan
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Jiwei Chen
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Da Wang
- East China Normal University and Shanghai Changzheng Hospital Joint Research Center for Orthopedic Oncology, East China Normal University
- Qing Zhang
- Department of Hematology, Guangdong Second Provincial General Hospital
- Shihui Shen
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Yu Xiao
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Zhipeng Wu
- East China Normal University and Shanghai Changzheng Hospital Joint Research Center for Orthopedic Oncology, East China Normal University
- Yiyun Cheng
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Geng Chen
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Syeda Kubra
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Jun Qin
- The Joint Laboratory of Translational Medicine, National Center for Protein Sciences (Beijing) and Peking University Cancer Hospital, State Key Laboratory of Proteomics, Institute of Lifeomics
- Lan Huang
- Department of Physiology and Biophysics, University of California
- Pei Zhang
- Department of Pathology, The Second Chengdu Municipal Hospital
- Chuangui Wang
- Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Robb E. Moses
- Department of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Baylor College of Medicine
- David M. Lonard
- Department of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Baylor College of Medicine
- Bert W. O’ Malley
- Department of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Baylor College of Medicine
- Fuad Fares
- Department of Human Biology. Faculty of Natural Sciences, University of Haifa
- Bianhong Zhang
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Xiaotao Li
- East China Normal University and Shanghai Changzheng Hospital Joint Research Center for Orthopedic Oncology, East China Normal University
- Lei Li
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University
- Jianru Xiao
- East China Normal University and Shanghai Changzheng Hospital Joint Research Center for Orthopedic Oncology, East China Normal University
- DOI
- https://doi.org/10.1038/s41467-020-17667-7
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 10
Abstract
How the REGγ-proteasome pathway is regulated during the cell cycle or genotoxic insults remains unclear. Here, the authors show that NIP30 acts as a molecular switch to regulate the REGγ-proteasome activity and may provide an approach to combat drug-resistant tumours lacking functional p53.
